Aravax
Manufacturing · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
31 Queen St L 9, Melbourne, Victoria, 30...Phone Number
+61 396570700Website
www.aravax.com.auRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Aravax
Aravax is a clinical-stage biotechnology company focused on developing safe, convenient, and disease-modifying treatments for food allergies, particularly peanut allergy. Utilizing proprietary technology, Aravax aims to reset the immune system to tolerate allergens without severe reactions. The company has successfully completed Phase 1 clinical trials of its lead product, PVX108, and is currently active in Phase 2 trials involving adolescents and children. Aravax is committed to international expansion and enhancing its manufacturing capabilities.Explore more
Aravax Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aravax your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Aravax has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Aravax has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Aravax launches new products
Click to see if Aravax had a recent Job posting/layoffs
Check out if Aravax is spiking on competitors!
Earning: See what the market has to say on Aravax recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Aravax, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Aravax
Recommended Actions
Find VP level buyers at Aravax
Find 2 more new buyers
Compare Similar Companies to Aravax
Compare insights from companies similar to Aravax, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aravax is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aravax is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aravax.
Aravax Tech Stack
A closer look at the technologies used by Aravax
See more technologies
Aravax News & Media
Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development
MELBOURNE, Australia and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces the appointment of Louise Peacock as Chief Regulatory and Quality Officer, based at the Company’s Oxford, UK site.Aravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer
MELBOURNE, Australia and OXFORD, United Kingdom, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing precisely targeted next-generation immunotherapies for the treatment of food allergy, today announces the appointment of Aled Williams as Chief Business Officer as the company continues its development into an international leader in food allergies.Aravax Establishes Pharmaceutical Development base on the Oxford Science Park with a Focus on Developing Manufacturing Capabilities in the UK
MELBOURNE, Australia and OXFORD, United Kingdom, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies designed to be safe, convenient, and precisely targeted, today announces it has established a UK subsidiary, based on the Oxford Science Park, as the company continues its development into an international leader in food allergies.Aravax Completes Recruitment into Phase 2 Study of PVX108, a novel immunotherapy for the Treatment of Peanut Allergy
MELBOURNE, Australia, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies designed to be safe, convenient, and precisely targeted, today announces it has completed patient recruitment into its Phase 2 study (AVX-201) of its novel, precision therapy PVX108 for the treatment of peanut allergy.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Aravax
Sign Up For FreeTo access detailed company insights
Aravax is a clinical-stage biotechnology company focused on developing safe, convenient, and disease-modifying treatments for food allergies, particularly peanut allergy. Utilizing proprietary technology, Aravax aims to reset the immune system to tolerate allergens without severe reactions. The company has successfully completed Phase 1 clinical tr... Read More
